David J. Cohen

发表

Outcomes of Atrial Fibrillation Ablation in Patients With Metabolic Syndrome

C. Hamm, T. Neumann, M. Kuniss, 2012 .

Ticagrelor With Aspirin or Alone After Complex PCI: The TWILIGHT-COMPLEX Analysis.

Samin K. Sharma, S. Pocock, G. Dangas, 2020, Journal of the American College of Cardiology.

Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.

S. Pocock, G. Stone, T. Henry, 2016, Journal of the American College of Cardiology.

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Braunwald, S. Normand, E. Braunwald, 2014, The New England journal of medicine.

Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial.

Eric Peterson, David A Morrow, David J Cohen, 2006, Journal of the American College of Cardiology.

Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.

M. York, A. Lincoff, R. Mehran, 2008, Journal of the American College of Cardiology.

The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale.

Sunil V. Rao, L. Mauri, J. Lasala, 2019, American heart journal.

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

L. Deckelbaum, S. King, D. Cohen, 1998, Journal of the American College of Cardiology.

Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.

G. Dangas, U. Baber, B. Vogel, 2024, American heart journal.

Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)

S. Pocock, T. Henry, M. Krucoff, 2018, Circulation. Cardiovascular interventions.

Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.

G. Dangas, G. Weisz, U. Baber, 2023, JACC. Cardiovascular interventions.

Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events.

T. Ryan, H. Dauerman, A. Kirtane, 2008, American heart journal.

Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.

Samin K. Sharma, G. Dangas, S. Mehta, 2023, The American journal of cardiology.

Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome.

A. Kirtane, D. Morrow, S. Murphy, 2006, The American journal of cardiology.

Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk: A Cost Consequence Simulation From PARIS

S. Pocock, T. Henry, M. Krucoff, 2019, Circulation. Cardiovascular quality and outcomes.

S. Pocock, T. Henry, M. Krucoff, 2018 .

White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)

S. Pocock, Binita Shah, T. Henry, 2017, Circulation. Cardiovascular interventions.